Bil­lion­aire-backed Chi-Med de­clares PhI­II suc­cess for pi­o­neer­ing can­cer drug in Chi­na, seek­ing quick OK

Hutchi­son Chi­na MediTech has turned an im­por­tant cor­ner, scor­ing pos­i­tive over­all sur­vival and pro­gres­sion-free sur­vival in a Phase III study of fruquin­tinib, its lead on­col­o­gy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER